Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.

doi:10.1136/jitc-2024-008872

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.

Journal for immunotherapy of cancer - 6 Aug 2024

Schenker Michael, Burotto Mauricio, Richardet Martin, Ciuleanu Tudor-Eliade, Gonçalves Anthony, Steeghs Neeltje, Schoffski Patrick, Ascierto Paolo A, Maio Michele, Lugowska Iwona, Lupinacci Lorena, Leary Alexandra, Delord Jean-Pierre, Grasselli Julieta, Tan David S P, Friedmann Jennifer, Vuky Jacqueline, Tschaika Marina, Konduru Somasekhar, Vemula Sai Vikram, Slepetis Ruta, Kollia Georgia, Pacius Misena, Duong Quyen, Huang Ning, Doshi Parul, Baden Jonathan, Di Nicola Massimo

Abstract excerpt

BACKGROUND: Checkpoint inhibitor therapy has demonstrated overall survival benefit in multiple tumor types. Tumor mutational burden (TMB) is a predictive biomarker for response to immunotherapies. This study evaluated the efficacy of nivolumab+ipilimumab in multiple tumor types based on TMB status evaluated using either tumor tissue (tTMB) or circulating tumor DNA in the blood (bTMB). PATIENTS AND METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Ipilimumab

Share to Mutation

Share to Neoplasm Metastasis

Share to Neoplasms

Share to Nivolumab

Source

Open in PubMed Open full text

Identifiers

PMID: 39107131
DOI: 10.1136/jitc-2024-008872
PMCID: PMC11308901

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.PMID 39107131Read ↗

Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy.Semantic proximity Read ↗

Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.Semantic proximity Read ↗

Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.Semantic proximity Read ↗

A Systematic Review and Meta-Analysis of the Impact of Tumour Mutation Burden on Survival Outcomes in Solid TumoursSemantic proximity Read ↗

Tissue and Blood-Based Tumor Mutational Burden Predicts Treatment Response to PD-1 Blockade in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?Semantic proximity Read ↗

Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better.Semantic proximity Read ↗

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.Semantic proximity Read ↗

Interplay between Tumor Mutational Burden and Mutational Profile and its effect on overall survival: A Post Hoc Analysis of Metastatic Patients Treated with Immune Checkpoint InhibitorsSemantic proximity Read ↗

Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.Semantic proximity Read ↗

Tumor Mutational Burden as a Predictive Biomarker in Solid TumorsSemantic proximity Read ↗

FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.